Health Condition 1: E785- Hyperlipidemia, unspecified
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Cipla Limited
Eligibility
Inclusion criteria
Inclusion criteria: Primary CVD prevention patients ie patients with no history of atherosclerotic cardiovascular disease CVD but with risk factors for developing CVD as assessed from the clinical history documentation of the patient Patients who are initiated on a statin rosuvastatin or atorvastatin within the last 6 months as per the clinical judgement of the treating physician and are continuing the same dose or and require a dose modification as per clinical judgement of the treating physician in the current visit and Patients who are willing to provide informed written consent and agree to comply with the study procedures
Exclusion criteria
Exclusion criteria: Patients with known history of hypersensitivity eg anaphylaxis or angioedema to any component active and any excipients of the prescribed product rosuvastatin or atorvastatin Women who are pregnant or breastfeeding during study period Patients with acute liver failure or decompensated cirrhosis Patients who are participating in another clinical study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To identify characteristics of primary CVD prevention patients ie those who do not have a history of atherosclerotic CVD as per the dose of statins rosuvastatin 5mg or 10mg or 20mg or 40mg and atorvastatin 10mg or 20mg or 40mg or 80mgTimepoint: Single Visit | — |
Secondary
| Measure | Time frame |
|---|---|
| To analyse the association between the LDL C levels with dose of statin rosuvastatin or atorvastatin in patients already initiated on a statin rosuvastatin or atorvastatin To identify the risk factor/s that resulted in change in treatment decision in patients who were recommended a dose modification of statin rosuvastatin or atorvastatin in the current visit Compare the intensity of statin rosuvastatin or atorvastatin recommended as per ACC CV risk calculator with that observed actual clinical practice Timepoint: Single Visit | — |
Countries
India
Contacts
Public ContactMr Rahul Iyer
Cipla Limited
Outcome results
None listed